HSA
BEAM icon

Hussman Strategic Advisors’s Beam Therapeutics BEAM Stock Holding History

Hussman Strategic Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,600
Closed -$313K – 322
2021
Q3 		$313K Hold
3,600
– – 0.07% 276
2021
Q2 		$463K Hold
3,600
– – 0.1% 269
2021
Q1 		$288K Buy
+3,600
New +$342K 0.06% 296

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hussman Strategic Advisors's BEAM Position: Q4 2021 in Review

Hussman Strategic Advisors sold out of Beam Therapeutics (BEAM) in Q4 2021, closing a stake of 3,600 shares — an estimated $313K sold.

Hussman Strategic Advisors first reported a position in BEAM in Q1 2021 and held it in 3 quarters. The position peaked at $463K in Q2 2021. 232 funds tracked by Wall St. Rank hold BEAM as of Q4 2021.

  • Hussman Strategic Advisors reported no remaining Beam Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Hussman Strategic Advisors sold 3,600 Beam Therapeutics shares in Q4 2021, an estimated $313K.
  • Hussman Strategic Advisors first reported a position in Beam Therapeutics in Q1 2021 and held it in 3 quarters.
  • Hussman Strategic Advisors's Beam Therapeutics position peaked at $463K in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2021.

Based on Hussman Strategic Advisors's 13F filing for Q4 2021, filed 31 Jan 2022.